| pubmed-article:7006761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7006761 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7006761 | lifeskim:mentions | umls-concept:C0682526 | lld:lifeskim |
| pubmed-article:7006761 | lifeskim:mentions | umls-concept:C0012860 | lld:lifeskim |
| pubmed-article:7006761 | lifeskim:mentions | umls-concept:C0068314 | lld:lifeskim |
| pubmed-article:7006761 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:7006761 | lifeskim:mentions | umls-concept:C0085752 | lld:lifeskim |
| pubmed-article:7006761 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:7006761 | pubmed:dateCreated | 1981-4-21 | lld:pubmed |
| pubmed-article:7006761 | pubmed:abstractText | The adriamycin- and N-trifluoroacetyladriamycin-14-valerate (AD-32) induced DNA cross-linking and breakage in human RPMI-6410 cells was compared using the alkaline elution technique of Kohn and co-workers. At comparable growth-inhibitory concentrations both adriamycin and AD-32 caused DNA cross-linking. Treatment with proteinase-K showed this cross-linking to be mainly DNA-protein in character. Proteinase-K treatment also revealed that both drugs caused either single-strand DNA breaks or increased alkaline sensitivity. With adriamycin the degree of cross-linking and breakage was dose related over the range studied (0.05 - 0.4 micron/mL), whereas with AD-32 there appeared to be a saturation of both effects at concentrations in excess of 3 micron/mL. With both drugs the extent of cross-linking and breakage was maximal at the end of the drug exposure. This work suggests that AD-32 or some metabolite of its binds to DNA and this binding leads to DNA damage that is similar to that caused by adriamycin. These AD-32 results are somewhat surprising in light of earlier model studies showing that AD-32 does not bind to isolated DNA. | lld:pubmed |
| pubmed-article:7006761 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7006761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7006761 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7006761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7006761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7006761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7006761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7006761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7006761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7006761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7006761 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:7006761 | pubmed:issn | 0008-4018 | lld:pubmed |
| pubmed-article:7006761 | pubmed:author | pubmed-author:BroxLL | lld:pubmed |
| pubmed-article:7006761 | pubmed:author | pubmed-author:BelchAA | lld:pubmed |
| pubmed-article:7006761 | pubmed:author | pubmed-author:GowansBB | lld:pubmed |
| pubmed-article:7006761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7006761 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:7006761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7006761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7006761 | pubmed:pagination | 720-5 | lld:pubmed |
| pubmed-article:7006761 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:meshHeading | pubmed-meshheading:7006761-... | lld:pubmed |
| pubmed-article:7006761 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:7006761 | pubmed:articleTitle | N-trifluoroacetyladriamycin-14-valerate and adriamycin induced DNA damage in the RPMI-6410 human lymphoblastoid cell line. | lld:pubmed |
| pubmed-article:7006761 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7006761 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7006761 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
